REFERENCES

1. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008;68:3077-80.

2. Mader S, Pantel K. Liquid biopsy: current status and future perspectives. Oncol Res Treat 2017;40:404-8.

3. Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006;6:924-35.

4. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012;481:306-13.

5. Palmieri M, Baldassarri M, Fava F, et al. Two-point-NGS analysis of cancer genes in cell-free DNA of metastatic cancer patients. Cancer Med 2020;9:2052-61.

6. Braun S, Hepp F, Sommer HL, Pantel K. Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease. Int J Cancer 1999;84:1-5.

7. Ilié M, Hofman P. Pros: can tissue biopsy be replaced by liquid biopsy? Transl Lung Cancer Res 2016;5:420-3.

8. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.

9. Li BT, Stephens D, Chaft JE, et al. Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers. Ann Transl Med 2017;5:479.

10. Rossi G, Mu Z, Rademaker AW, et al. Cell-free DNA and circulating tumor cells: comprehensive liquid biopsy analysis in advanced breast cancer. Clin Cancer Res 2018;24:560-8.

11. Li H, Zhu R, Wang L, et al. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast. Exp Mol Pathol 2010;88:150-5.

12. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005;7:561-73.